FISETIN 60 caps

Fisetin's clinical potential is often limited by a fundamental formulation challenge: poor water solubility and a strong tendency to aggregate with lipids, both of which restrict its absorption when taken in standalone form. Research confirms this limitation directly, with native fisetin exhibiting low solubility (10.45 µg/mL) and oral bioavailability of just 44.1%, leaving much of its therapeutic potential unrealized in the body.

ROKIT America addresses this challenge head-on with a scientifically optimized formulation engineered specifically to enhance fisetin's bioavailability. The result is a product that delivers superior absorption and effectiveness, allowing consumers to access fisetin's full range of health benefits rather than a fraction of it.

Senescent cells are damaged or aging cells that have stopped functioning properly but refuse to die off naturally. Here's a simple breakdown:

What Happens Normally
Healthy cells follow a natural life cycle — they grow, function, and eventually die off in a controlled process to make room for new, healthy cells. This keeps your body running smoothly.

What Goes Wrong
When cells become too damaged to function,  whether from aging, stress, or DNA damage they're supposed to self-destruct. But sometimes they don't. Instead, they enter a "zombie-like" state where they stop doing their job but continue to linger in the body.

Why They're Harmful
These zombie cells aren't just inactive, they can be actively damaging. They release a toxic cocktail of inflammatory chemicals into surrounding tissue, which over time:

• Damages neighboring healthy cells
• Drives chronic inflammation
• Accelerates the aging process
• Has been linked to conditions like arthritis, heart disease, diabetes, and cognitive decline

Why They Accumulate
When we're young, our immune system is efficient at identifying and clearing out senescent cells. As we age, this process becomes less effective, allowing zombie cells to build up in tissues and organs throughout the body.

Why It Matters
Senescent cell accumulation is now considered one of the key drivers of biological aging. Clearing them out is key, which is exactly what senolytics like fisetin are designed to do. 

 In a landmark 2018 study, researchers screened 10 flavonoid compounds for senolytic activity in senescent mouse and human cells, and fisetin emerged as the most potent. In mice, both acute and intermittent fisetin treatment reduced senescence markers across multiple tissues. Most notably, administering fisetin to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology, and extended both median and maximum lifespan. This is animal-model evidence, not a human outcome, but it's the study that established fisetin's reputation and launched the current wave of human trials.

In vitro research shows fisetin's senolytic action appears to selectively target senescent cells while sparing healthy ones. Researchers describe fisetin as acting on specific "senescent cell anti-apoptotic pathways" (SCAPs), essentially proteins that senescent cells rely on to resist their own natural cell death. This cell-culture-level selectivity is what distinguishes a true senolytic from a generic cytotoxic compound, and it's the mechanistic basis researchers cite for why fisetin can be studied without expecting broad, indiscriminate cell death.

Yes, a study in old mice found that intermittent fisetin supplementation improved arterial function by reducing cellular senescence in blood vessels. Using a genetic mouse model that allowed researchers to selectively remove senescent cells, they confirmed the improvement was specifically due to senolysis (clearing senescent cells), fisetin-treated mice showed lower arterial stiffness, better endothelium-dependent dilation, and reduced oxidative stress, mediated by increased nitric oxide availability. This is a well-designed animal study that isolates the mechanism, but it hasn't yet been replicated as a vascular outcome in a human trial.

Yes, this is an important nuance often missed in fisetin discussions. The foundational 2018 study that established fisetin's reputation for extending lifespan actually used continuous dietary supplementation, not a short pulse. Researchers fed mice a diet containing fisetin (500 mg/kg of diet) continuously, starting at 85 weeks of age (roughly equivalent to a 75-year-old human), and sustained that exposure. This chronic-exposure protocol is what produced the study's headline finding: extended median and maximum lifespan in aged mice.

Yes. The same study also tested chronic, diet-based fisetin exposure in a separate mouse model of accelerated aging (progeroid mice) and found it reduced markers of cellular senescence and SASP (senescence-associated inflammatory factors) across multiple tissues, alongside reduced markers of oxidative stress in the liver.

This appears to be a practical and safety consideration for human translation rather than evidence that chronic dosing doesn't work. Later, more targeted animal studies (on vascular function and skeletal muscle specifically) intentionally used intermittent dosing to isolate the senolytic mechanism and to mirror the dosing paradigm used in human clinical trials — and trial designers have explicitly cited reduced side-effect risk and fewer drug interactions as reasons for choosing intermittent human protocols. In other words: pulsed dosing became the human standard largely for tolerability and trial-design reasons, not because chronic dosing was shown to be inferior in animals.